Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Department of Biostatistics, University of North Carolina, Chapel Hill, NC, USA.
BMC Genomics. 2024 May 8;25(1):452. doi: 10.1186/s12864-024-10226-0.
Apolipoprotein L1 (APOL1) coding variants, termed G1 and G2, are established genetic risk factors for a growing spectrum of diseases, including kidney disease, in individuals of African ancestry. Evidence suggests that the risk variants, which show a recessive mode of inheritance, lead to toxic gain-of-function changes of the APOL1 protein. Disease occurrence and presentation vary, likely due to modifiers or second hits. To understand the role of the epigenetic landscape in relation to APOL1 risk variants, we performed methylation quantitative trait locus (meQTL) analysis to identify differentially methylated CpGs influenced by APOL1 risk variants in 611 African American individuals. We identified five CpGs that were significantly associated with APOL1 risk alleles in discovery and replication studies, and one CpG-APOL1 association was independent of other genomic variants. Our study highlights proximal DNA methylation alterations that may help explain the variable disease risk and clinical manifestation of APOL1 variants.
载脂蛋白 L1 (APOL1) 编码变异体,称为 G1 和 G2,是非洲裔个体中一系列疾病(包括肾脏疾病)的既定遗传风险因素。有证据表明,这些表现为隐性遗传模式的风险变异导致 APOL1 蛋白的毒性获得性功能改变。疾病的发生和表现可能因修饰因子或第二打击而有所不同。为了了解表观遗传景观与 APOL1 风险变异体的关系,我们进行了甲基化定量性状基因座 (meQTL) 分析,以鉴定受 APOL1 风险变异体影响的差异甲基化 CpG 在 611 名非裔美国人个体中的位置。我们在发现和复制研究中鉴定了五个与 APOL1 风险等位基因显著相关的 CpG,其中一个 CpG-APOL1 关联与其他基因组变异无关。我们的研究强调了近端 DNA 甲基化改变,这可能有助于解释 APOL1 变异体的可变疾病风险和临床表现。